Literature DB >> 18097548

Oncogenic mutations of the PIK3CA gene in head and neck squamous cell carcinomas.

Avaniyapuram Kannan Murugan1, Nguyen Thi Hong, Yasuhisa Fukui, Arasambattu Kannan Munirajan, Nobuo Tsuchida.   

Abstract

Phosphatidylinositol 3-kinases (PI3Ks) are heterodimeric lipid kinases that regulate cellular activities such as proliferation, survival, motility and morphology. Recent studies reported that the p110alpha (PIK3CA), catalytic subunit of PI3-kinase is somatically mutated in human cancers. Hot- spot mutations (E542K, E545K and H1047R) are reported to have higher oncogenic potential. Although PIK3CA mutations were reported in head and neck squamous cell carcinomas (HNSCC) of limited ethnicity, the functional consequences of HNSCC-associated PIK3CA mutations have not been examined. Status of PI3K signaling related genes (PTEN-RAS-EGFR) in the presence of PIK3CA mutation have not been reported. In this study, we analyzed exons 9 and 20 of PIK3CA in 54 samples, including 17 HNSCC cell lines, 19 Indian and 18 Vietnamese primary tumors. We found mutations in 29.4% (5/17) of HNSCC cell lines, 10.5% (2/19) of Indian tumors and no mutation (0/18) in Vietnamese tumors. Two homozygous PIK3CA mutations were found in cell lines and a novel insertion mutation with oncogenicity in Indian tumor. Analysis of PI3K signaling related genes showed that PIK3CA and PTEN mutations were mutually exclusive, though PTEN mutation is uncommon in HNSCC. However, PIK3CA mutation coexisted with H-RAS mutation. Furthermore, PIK3CA mutations were mutually exclusive to EGFR amplification. All the 5 mutants that we found in HNSCC, showed increased PI3 kinase activities, followed by growth factor independent higher colony forming efficiency, changes in morphology, higher rates of migration and invasion compared with PIK3CA wild-type. Our study is the first to examine the oncogenic potential of PIK3CA mutants associated with HNSCC and report on PIK3CA mutations in Indian and Vietnamese ethnicity. These results suggest that PIK3CA mutations in HNSCC are likely to be oncogenic and may significantly contribute to HNSCC carcinogenesis and pave attractive target for therapeutic prevention.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18097548

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  50 in total

Review 1.  Oncogenic mutations of PIK3CA in human cancers.

Authors:  Yardena Samuels; Todd Waldman
Journal:  Curr Top Microbiol Immunol       Date:  2010       Impact factor: 4.291

2.  Feasibility of Targeting PIK3CA Mutations in Head and Neck Squamous Cell Carcinoma.

Authors:  Julie A Theurer; William Stecho; John Yoo; Keith Kwan; Bret Wehrli; Vimla Harry; Morgan Black; Nicole Pinto; Eric Winquist; David Palma; Suzanne Richter; John W Barrett; S Danielle MacNeil; Kevin Fung; Christopher J Howlett; Anthony C Nichols
Journal:  Pathol Oncol Res       Date:  2015-08-14       Impact factor: 3.201

3.  Identification and functional characterization of isocitrate dehydrogenase 1 (IDH1) mutations in thyroid cancer.

Authors:  Avaniyapuram Kannan Murugan; Ermal Bojdani; Mingzhao Xing
Journal:  Biochem Biophys Res Commun       Date:  2010-02-18       Impact factor: 3.575

Review 4.  Dysregulated molecular networks in head and neck carcinogenesis.

Authors:  Alfredo A Molinolo; Panomwat Amornphimoltham; Cristiane H Squarize; Rogerio M Castilho; Vyomesh Patel; J Silvio Gutkind
Journal:  Oral Oncol       Date:  2008-09-19       Impact factor: 5.337

Review 5.  Mutation distributions and clinical correlations of PIK3CA gene mutations in breast cancer.

Authors:  Ebubekir Dirican; Mustafa Akkiprik; Ayşe Özer
Journal:  Tumour Biol       Date:  2016-02-26

6.  High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability.

Authors:  Lydia W T Cheung; Bryan T Hennessy; Jie Li; Shuangxing Yu; Andrea P Myers; Bojana Djordjevic; Yiling Lu; Katherine Stemke-Hale; Mary D Dyer; Fan Zhang; Zhenlin Ju; Lewis C Cantley; Steven E Scherer; Han Liang; Karen H Lu; Russell R Broaddus; Gordon B Mills
Journal:  Cancer Discov       Date:  2011-06-07       Impact factor: 39.397

7.  The determinants of head and neck cancer: Unmasking the PI3K pathway mutations.

Authors:  Fernanda S Giudice; Cristiane H Squarize
Journal:  J Carcinog Mutagen       Date:  2013-08-02

Review 8.  Lessons learned from next-generation sequencing in head and neck cancer.

Authors:  Myriam Loyo; Ryan J Li; Chetan Bettegowda; Curtis R Pickering; Mitchell J Frederick; Jeffrey N Myers; Nishant Agrawal
Journal:  Head Neck       Date:  2012-08-21       Impact factor: 3.147

9.  Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers.

Authors:  Vivian W Y Lui; Matthew L Hedberg; Hua Li; Bhavana S Vangara; Kelsey Pendleton; Yan Zeng; Yiling Lu; Qiuhong Zhang; Yu Du; Breean R Gilbert; Maria Freilino; Sam Sauerwein; Noah D Peyser; Dong Xiao; Brenda Diergaarde; Lin Wang; Simion Chiosea; Raja Seethala; Jonas T Johnson; Seungwon Kim; Umamaheswar Duvvuri; Robert L Ferris; Marjorie Romkes; Tomoko Nukui; Patrick Kwok-Shing Ng; Levi A Garraway; Peter S Hammerman; Gordon B Mills; Jennifer R Grandis
Journal:  Cancer Discov       Date:  2013-04-25       Impact factor: 39.397

10.  Improving Response Rates to EGFR-Targeted Therapies for Head and Neck Squamous Cell Carcinoma: Candidate Predictive Biomarkers and Combination Treatment with Src Inhibitors.

Authors:  Ann Marie Egloff; Jennifer Rubin Grandis
Journal:  J Oncol       Date:  2009-07-14       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.